SCHEMBL24974651

SCHEMBL24974651

O=C(O)CCS(=O)(=O)N1CCC(C2CC(=O)N(c3ccccc3)C2=O)CC1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MT-CO2 P00403 7/20 0.45
ALOX5 P09917 7/20 0.45
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 2/20 0.41
MCL1 Q07820 1/20 0.41
ALDH1A1 P00352 4/20 0.39
MAPT P10636 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
GAA P10253 1/20 0.39
GFER P55789 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
HSP90AA1 P07900 1/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24974652 0.87 MT-CO2 (0.42) MT-CO2ALOX5KMT2AMEN1POLB
SCHEMBL21150757 0.76 ALDH1A1 (0.39) KMT2AMEN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL21150773 0.70 ITGB3 (0.47) POLBGAALMNA
SCHEMBL24974751 0.69 ALDH1A1 (0.38) KMT2AMEN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL21150756 0.66 GPR119 (0.37) MT-CO2ALOX5KMT2AMEN1ALDH1A1
SCHEMBL19402721 0.66 APEX1 (0.50) POLBALDH1A1TDP1GAASMN1; SMN2
SCHEMBL13483191 0.65 POLB (0.75) MT-CO2ALOX5POLBALDH1A1MAPT
SCHEMBL24974367 0.64 SMN1; SMN2 (0.40) KMT2AMEN1GAASMN1; SMN2
SCHEMBL9479020 0.63 MT-CO2 (0.50) MT-CO2ALOX5POLBMCL1ALDH1A1
SCHEMBL5691873 0.63 MT-CO2 (0.56) MT-CO2ALOX5POLBALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572370-B2 CD16A binding agents and uses thereof BIOHAVEN THERAPEUTICS LTD. (US) 2023-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572370-B2 CD16A binding agents and uses thereof FCGR1A, FCGR2A, FCGR3B MT-CO2 4876/4885ALOX5 1220/4885KMT2A 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.